A phase I/II study of preoperative oxaliplatin (O), 5-fluorouracil (5-FU), and external beam radiation therapy (XRT) in locally advanced rectal cancer: CALGB 89901

Ryan, D. P.; Niedzwiecki, Donna; Hollis, Donna; Miedema, Baujke; Wadler, Scott; Tepper, Joel E.; Mayer, Ruth

doi:10.1200/jco.2004.22.14_suppl.3560

Cited by 5 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In collaboration with GI Committee investigators, CALGB radiation oncologists performed a critical phase I/II evaluation of the maximum radiation dose that could be safely administered concurrently with 5FU and oxaliplatin in patients with locally advanced rectal cancer. 79 Based on a 25% pathologic complete response rate for patients treated at the 60 Gy dose, this regimen has been taken forward as one of the arms of an ongoing randomized trial in rectal cancer patients sponsored by the GI Intergroup.…”

Section: Radiation Oncologymentioning

confidence: 99%

Tomorrow's Cancer Treatments Today: The First 50 Years of the Cancer and Leukemia Group B

Green

George

Schilsky

2008

Seminars in Oncology

View full text Add to dashboard Cite

Members of the Cancer and Leukemia Group B have been striving to improve cancer therapies for more than 50 years. The organization began in the mid 1950s as a multi-institutional collaboration between investigators at the National Cancer Institute, Roswell Park Memorial Institute, and the Children’s Hospital in Buffalo New York. In 1956 it was officially designated as the Acute Leukemia Group B (ALGB) and for most of its first decade focused largely on leukemia research. Reflecting an expansion of its research portfolio during the 1960s and 70s, the name was changed in 1976 to Cancer and Leukemia Group B (CALGB). Currently the organization has hundreds of members including nurses, clinical research associates, statisticians, physicians, translational scientists, and an administrative staff from a nationwide network of academic and community based organizations and medical practices. Disease areas within the scope of CALGB research include hematologic malignancies, as well as breast, gastro-intestinal, genito-urinary, and respiratory cancers. Modality expertise includes quality of life, medical oncology, surgery, radiation oncology, pathology, imaging, oncology nursing, health outcomes, geriatrics, biostatistics, data management, and an extensive array of correlative sciences. Some of the major accomplishments of CALGB investigators and the patients participating in CALGB research as critical and committed partners will be reviewed in this manuscript.

show abstract

Section: Radiation Oncologymentioning

confidence: 99%

Tomorrow's Cancer Treatments Today: The First 50 Years of the Cancer and Leukemia Group B

Green

George

Schilsky

2008

Seminars in Oncology

View full text Add to dashboard Cite

show abstract

“…Several phase I and II trials have confirmed the feasibility and tolerance of oxaliplatin with 5-FU neoadjuvant CMT. [111][112][113][114][115][116] Similarly many neoadjuvant trials are examining the possibility of adding irinotecan to the CMT regimen based on the its successful utilization in advanced colorectal cancers. 117,118 Irinotecan inhibits the nuclear enzyme topo-1 by binding and stabilizing the topo-1/DNA cleavable complex.…”

Section: Oxaliplatin and Irinotecanmentioning

confidence: 99%